Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas

Oncotarget

Volumn 4, Issue 11, 2013, Pages 1919-1932

  Fraile, Julia M ^a   Ordóñez, Gonzalo R ^a   Quirós, Pedro M ^a   Astudillo, Aurora ^b   Galván, José A ^b   Colomer, Dolors ^c   López Otín, Carlos ^a   Freije, José M P ^a   Puente, Xose S ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cancer; Invasion; Metastasis; Proteolysis

Indexed keywords

CAENORHABDITIS ELEGANS PROTEIN; NUD 1 PROTEIN, C ELEGANS; NUD-1 PROTEIN, C ELEGANS; PEPTIDE HYDROLASE; PROTEINASE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CACO 2 CELL LINE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENICITY; CELL GROWTH; COLON MUCOSA; COLORECTAL CARCINOMA; COLORECTAL TUMOR; DEGRADOME PROFILING; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LOCALIZATION; ENZYMOLOGY; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; GENETICS; GENOMICS; HCT116 CELL LINE; HEK293 CELL LINE; HUMAN; MASP3 GENE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SOMATIC MUTATION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANIMALS; CACO-2 CELLS; CAENORHABDITIS ELEGANS PROTEINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; ENZYMOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETICS; HCT116 CELLS; HEK293 CELLS; HUMANS; METABOLISM; MICE; MICE, NUDE; PATHOLOGY; PEPTIDE HYDROLASES; PHYSIOLOGY; TRANSFECTION;

EID: 84890187212     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1303     Document Type: Article

References (47)

1. Lopez-Otin C and Bond JS. Proteases: multifunctional enzymes in life and disease. J Biol Chem. 2008; 283(45):30433-30437.
2. Turk B, Turk DS and Turk V. Protease signalling: the cutting edge. EMBO J. 2012.
3. Puente XS and Lopez-Otin C. A genomic analysis of rat proteases and protease inhibitors. Genome Res. 2004; 14(4):609-622.
4. Puente XS, Gutierrez-Fernandez A, Ordonez GR, Hillier LW and Lopez-Otin C. Comparative genomic analysis of human and chimpanzee proteases. Genomics. 2005; 86(6):638-647.
5. Quesada V, Velasco G, Puente XS, Warren WC and Lopez-Otin C. Comparative genomic analysis of the zebra finch degradome provides new insights into evolution of proteases in birds and mammals. BMC Genomics. 2010; 11(1):220.
6. Lopez-Otin C and Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol. 2002; 3(7):509-519.
7. Overall CM and Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002; 2(9):657-672.
8. Kessenbrock K, Plaks V and Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67.
9. Lopez-Otin C and Hunter T. The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer. 2010; 10(4):278-292.
10. Mason SD and Joyce JA. Proteolytic networks in cancer. Trends Cell Biol. 2011; 21(4):228-237.
11. Wei X, Prickett TD, Viloria CG, Molinolo A, Lin JC, Cardenas-Navia I, Cruz P, Rosenberg SA, Davies MA, Gershenwald JE, Lopez-Otin C and Samuels Y. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol Cancer Res. 2010; 8(11):1513-1525.
12. Wei X, Moncada-Pazos A, Cal S, Soria-Valles C, Gartner J, RudloffU, Lin JC, Rosenberg SA, Lopez-Otin C and Samuels Y. Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma. Hum Mutat. 2011; 32(6):E2148-2175.
13. Saggar S, ChernoffKA, Lodha S, Horev L, Kohl S, Honjo RS, Brandt HR, Hartmann K and Celebi JT. CYLD mutations in familial skin appendage tumours. J Med Genet. 2008; 45(5):298-302.
14. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C and Bowcock AM. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010; 330(6009):1410-1413.
15. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y and Seto M. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood. 2009; 114(12):2467-2475.
16. Soung YH, Lee JW, Kim SY, Jang J, Park YG, Park WS, Nam SW, Lee JY, Yoo NJ and Lee SH. CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res. 2005; 65(3):815-821.
17. Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL, Matta H, Miyajima K, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Chaudhary PM and Gazdar AF. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 2002; 62(20):5897-5901.
18. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K and Massague J. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 2007; 446(7137):765-770.
19. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M and Hanahan D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004; 5(5):443-453.
20. Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn HJ, Benz C, Eppenberger U and Eppenberger-Castori S. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol. 2006; 24(26):4245-4253.
21. Luise C, Capra M, Donzelli M, Mazzarol G, Jodice MG, Nuciforo P, Viale G, Di Fiore PP and Confalonieri S. An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS One. 2011; 6(1):e15891.
22. Lopez-Otin C and Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer. 2007; 7(10):800-808.
23. Fraile JM, Quesada V, Rodriguez D, Freije JM and Lopez-Otin C. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene. 2012; 31(19):2373-2388.
24. Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A, Overall CM, Shapiro SD and Lopez-Otin C. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet. 2003; 35(3):252-257.
25. AcuffHB, Sinnamon M, Fingleton B, Boone B, Levy SE, Chen X, Pozzi A, Carbone DP, Schwartz DR, Moin K, Sloane BF and Matrisian LM. Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res. 2006; 66(16):7968-7975.
26. Houghton AM, Grisolano JL, Baumann ML, Kobayashi DK, Hautamaki RD, Nehring LC, Cornelius LA and Shapiro SD. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res. 2006; 66(12):6149-6155.
27. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314(5797):268-274.
28. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, Escaramis G, Jares P, Bea S, Gonzalez-Diaz M, Bassaganyas L, Baumann T, Juan M, Lopez-Guerra M, Colomer D, Tubio JM, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011; 475(7354):101-105.
29. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, Bea S, Pinyol M, Martinez-Trillos A, Lopez-Guerra M, Colomer D, Navarro A, Baumann T, Aymerich M, Rozman M, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012; 44(1):47-52.
30. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science. 2011; 331(6024):1553-1558.
31. Goerge T, Barg A, Schnaeker EM, Poppelmann B, Shpacovitch V, Rattenholl A, Maaser C, Luger TA, SteinhoffM and Schneider SW. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res. 2006; 66(15):7766-7774.
32. Lynch CC, Crawford HC, Matrisian LM and McDonnell S. Epidermal growth factor upregulates matrix metalloproteinase-7 expression through activation of PEA3 transcription factors. Int J Oncol. 2004; 24(6):1565-1572.
33. Henkhaus RS, Gerner EW and Ignatenko NA. Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells. Biol Chem. 2008; 389(6):757-764.
34. McIver CM, Lloyd JM, Hewett PJ and Hardingham JE. Dipeptidase 1: a candidate tumor-specific molecular marker in colorectal carcinoma. Cancer Lett. 2004; 209(1):67-74.
35. Wilson CL, Heppner KJ, Labosky PA, Hogan BL and Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A. 1997; 94(4):1402-1407.
36. Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO and Lothe RA. ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol. 2006; 28(5-6):259-272.
37. Bister VO, Salmela MT, Karjalainen-Lindsberg ML, Uria J, Lohi J, Puolakkainen P, Lopez-Otin C and Saarialho-Kere U. Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Dig Dis Sci. 2004; 49(4):653-661.
38. Viloria CG, Obaya AJ, Moncada-Pazos A, Llamazares M, Astudillo A, Capella G, Cal S and Lopez-Otin C. Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. Cancer Res. 2009; 69(11):4926-4934.
39. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318(5853):1108-1113.
40. Freije JM, Fraile JM and Lopez-Otin C. Protease addiction and synthetic lethality in cancer. Front Oncol. 2011; 1:25.
41. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med. 2006; 354(23):2463-2472.
42. Bradford JR, Hey Y, Yates T, Li Y, Pepper SD and Miller CJ. A comparison of massively parallel nucleotide sequencing with oligonucleotide microarrays for global transcription profiling. BMC Genomics. 2010; 11:282.
43. Schwaeble W, Dahl MR, Thiel S, Stover C and Jensenius JC. The mannan-binding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes. Immunobiology. 2002; 205(4-5):455-466.
44. Cortesio CL and Jiang W. Mannan-binding lectin-associated serine protease 3 cleaves synthetic peptides and insulin-like growth factor-binding protein 5. Arch Biochem Biophys. 2006; 449(1-2):164-170.
45. Tonner E, Allan G, Shkreta L, Webster J, Whitelaw CB and Flint DJ. Insulin-like growth factor binding protein-5 (IGFBP-5) potentially regulates programmed cell death and plasminogen activation in the mammary gland. Adv Exp Med Biol. 2000; 480:45-53.
46. Akkiprik M, Feng Y, Wang H, Chen K, Hu L, Sahin A, Krishnamurthy S, Ozer A, Hao X and Zhang W. Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer. Breast Cancer Res. 2008; 10(4):212.
47. Quesada V, Ordonez GR, Sanchez LM, Puente XS and Lopez-Otin C. The Degradome database: mammalian proteases and diseases of proteolysis. Nucleic Acids Res. 2009; 37(Database issue):D239-243.